Sanofi: Covid-19 drug Kevzara fails clinical trial
(CercleFinance.com) - Sanofi has announced that the phase III trial evaluating Kevzara in patients who are hospitalised with a severe or critical form of Covid-19 did not meet its primary and secondary endpoints compared to placebo and in addition to usual hospital care.
This randomised trial included 420 patients and was conducted outside the United States, in countries such as Brazil, Canada, France, Germany, Italy, Japan, Russia and Spain, divided into three placebo groups, Kevzara 200 mg and Kevzara 400 mg.
Detailed results will be submitted to a scientific publication during the year. At present, neither Sanofi nor Regeneron foresee further clinical studies on Kevzara in the treatment of Covid-19.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
This randomised trial included 420 patients and was conducted outside the United States, in countries such as Brazil, Canada, France, Germany, Italy, Japan, Russia and Spain, divided into three placebo groups, Kevzara 200 mg and Kevzara 400 mg.
Detailed results will be submitted to a scientific publication during the year. At present, neither Sanofi nor Regeneron foresee further clinical studies on Kevzara in the treatment of Covid-19.
Copyright (c) 2020 CercleFinance.com. All rights reserved.